Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01431274 · ClinicalTrials.gov registry record · Phase 3
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,624
- Enrollment target
- 20
- Study locations
NCT01431274 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,624 participants, above the 1,009-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (160% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01431274, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,624 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).
Conditions Studied
Interventions
- DRUG tiotropium + olodaterol
- DRUG tiotropium
- DRUG olodaterol
Study Locations (20)
Florida
- 1237.5.01003 Boehringer Ingelheim Investigational Site - Clearwater
- 1237.5.01010 Boehringer Ingelheim Investigational Site - Clearwater
- 1237.5.01027 Boehringer Ingelheim Investigational Site - Panama City
Alabama
- 1237.5.01038 Boehringer Ingelheim Investigational Site - Jasper
- 1237.5.01036 Boehringer Ingelheim Investigational Site - Mobile
Colorado
- 1237.5.01015 Boehringer Ingelheim Investigational Site - Boulder
- 1237.5.01024 Boehringer Ingelheim Investigational Site - Wheat Ridge
Louisiana
- 1237.5.01035 Boehringer Ingelheim Investigational Site - Opelousas
- 1237.5.01004 Boehringer Ingelheim Investigational Site - Shreveport
New York
- 1237.5.01025 Boehringer Ingelheim Investigational Site - Larchmont
- 1237.5.01008 Boehringer Ingelheim Investigational Site - Rochester
North Carolina
- 1237.5.01023 Boehringer Ingelheim Investigational Site - Raleigh
- 1237.5.01016 Boehringer Ingelheim Investigational Site - Tabor City
Connecticut
- 1237.5.01034 Boehringer Ingelheim Investigational Site - Stamford
Illinois
- 1237.5.01031 Boehringer Ingelheim Investigational Site - O'Fallon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,624 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01431274
The ClinicalTrials.gov registry entry for NCT01431274 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,624 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,009-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (160% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 3 interventions - of which tiotropium + olodaterol is the first listed.
NCT01431274 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT01431274 about?
NCT01431274 is a clinical study titled "Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)". The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patie...
What is the current status of trial NCT01431274?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,624 participants. The study started on 2011-09. Estimated completion is 2013-09.
What conditions does trial NCT01431274 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT01431274?
The interventions under investigation include: tiotropium + olodaterol (DRUG), tiotropium (DRUG), olodaterol (DRUG).
Who is sponsoring clinical trial NCT01431274?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01431274 being conducted?
This trial has 20 study locations across Alabama, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.